People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma.

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Acromegaly is a rare endocrine disorder characterised by the excessive secretion of growth hormone (GH), most frequently resulting from a benign pituitary adenoma. The consequent overproduction of ...

In acromegaly, the excessive production of growth hormone and insulin-like growth factor 1 [IGF-1] causes several symptoms, including enlarged facial features, enlarged hands and feet, joint pain ...